Boston Scientific (BSX) to Acquire Intera Oncology
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/10/2026
- Wall St dips as tech declines, Middle East tensions mount
- Oil prices rise after Trump says Iran must pay price
- Oracle reports earnings today: Analysts say this metric could 'catalyze higher multiples'
- UBS sees generational semiconductor boom, highlights stock winners
- Has Tesla solved the self-driving puzzle? This analyst thinks so
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- Micron to deliver 'another strong quarter', Goldman says
- Needham Starts Hyliion Holdings (HYLN) at Buy
- UK's Ofcom requires tech firms to create crisis response plans
- Supermicro plans $7 billion financing to fund AI server orders
Boston Scientific Announces Agreement to Acquire Intera Oncology® Inc.
November 25, 2024 7:00 AM ESTAcquisition to expand interventional oncology offerings with complementary therapy to treat liver-dominant metastases
MARLBOROUGH, Mass., Nov. 25, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Intera Oncology® Inc., a privately held medical device company that provides the Intera 3000 Hepatic Artery Infusion Pump and floxuridine a chemotherapy drug both of which are approved by the... More
